“…The monovalent cation lithium (Li+) has been the subject of experimentation since it was first observed to induce a leukocytosis when administered to manic-depressive pa tients receiving Li+ as therapy [1,2]. Due to this inherent property, Li+ has been proposed as adjuvant therapy for the amelioration or prevention of the myelosuppression present in patients undergoing chemo and/or radio therapy [3][4][5][6][7][8][9][10][11][12][13], Investigations into the mechanism(s) by which Li+ induces increased myelopoiesis have suggested the following: (1) increased leukocyte release from the marrow reserves into the peripheral circulation [14]; (2) in creased synthesis and release of colony stim ulating factor (GM-CSF) from a wide variety of tissues [15,16], and (3) increased numbers of committed granulocyte-macrophage stem cells (CFU-GM) from a variety of species including man [6,14,[17][18][19][20], Li+ has been demonstrated to recruit CFU-GM into cell cycle as quantitated by measuring increased thymidine and hydroxyurea kill [21].…”